Protagonist: J&J, Protagonist outline first IBD win for potential immunological blockbuster

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the drug, known ...